↓ Skip to main content

National Trends in Ambulatory Oral Anticoagulant Use

Overview of attention for article published in American Journal of Medicine, December 2015
Altmetric Badge
69

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
8 news outlets
blogs
2 blogs
twitter
16 tweeters
wikipedia
1 Wikipedia page

Citations

dimensions_citation
160 Dimensions

Readers on

mendeley
129 Mendeley
Title
National Trends in Ambulatory Oral Anticoagulant Use
Published in
American Journal of Medicine, December 2015
DOI 10.1016/j.amjmed.2015.05.044
Pubmed ID
Authors

Geoffrey D. Barnes, Eleanor Lucas, G. Caleb Alexander, Zachary D. Goldberger

Abstract

Four direct oral anticoagulants (DOACs) have been brought to market for the treatment of nonvalvular atrial fibrillation and venous thromboembolism. Many forces, including numerous positive trial results, emerging safety concerns, marketing and promotion may shape DOAC adoption by providers. However, relatively little is known regarding their ambulatory utilization compared with warfarin, as well as the degree to which they have decreased undertreatment of atrial fibrillation. We used the IMS Health National Disease and Therapeutic Index, a nationally representative audit of outpatient office visits, to estimate the use of warfarin and DOACs between 2009 and 2014. Overall, visits with anticoagulation use increased from 2.05 (95% CI 1.82-2.27) to 2.83 (95% CI 2.49-3.17) million (M) quarterly visits (p<0.001). Of these, DOAC use has grown to 4.21M (95% CI 3.63M-4.79M; 38.2% of total) treatment visits in 2014 since their introduction in 2010. Use of all oral anticoagulants in treatment visits for atrial fibrillation has increased from 0.88M (95% CI 0.74M-1.02M) to 1.72M (95% CI 1.47M -1.97M; p<0.001), with similar DOAC and warfarin use in 2014. Atrial Fibrillation visits with anticoagulant use increased from 51.9% (95% CI 50.4%-53.8%) to 66.9% (95% CI 65.0%-69.3%) between 2009 and 2014 (p<0.001). In 2014, rivaroxaban was the most commonly prescribed DOAC for atrial fibrillation (47.9% of office visits), followed by apixaban (26.5%) and dabigatran (25.5%). DOACs have been rapidly adopted, matching the use of warfarin, and are associated with increased use of oral anticoagulation for patients with atrial fibrillation.

Twitter Demographics

The data shown below were collected from the profiles of 16 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 129 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 2 2%
Slovenia 1 <1%
Italy 1 <1%
France 1 <1%
Unknown 124 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 21 16%
Researcher 20 16%
Other 20 16%
Student > Doctoral Student 15 12%
Student > Postgraduate 13 10%
Other 40 31%
Readers by discipline Count As %
Medicine and Dentistry 75 58%
Unspecified 22 17%
Pharmacology, Toxicology and Pharmaceutical Science 17 13%
Biochemistry, Genetics and Molecular Biology 3 2%
Engineering 3 2%
Other 9 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 69. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2018.
All research outputs
#205,217
of 12,293,535 outputs
Outputs from American Journal of Medicine
#102
of 5,689 outputs
Outputs of similar age
#4,970
of 238,694 outputs
Outputs of similar age from American Journal of Medicine
#3
of 111 outputs
Altmetric has tracked 12,293,535 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,689 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 238,694 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 111 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.